In Arizona and across states with abortion bans, patients facing miscarriage treatment now encounter diminishing access to the most effective care, according to a new study released by the Journal of the American Medical Association. The research brings attention to evolving practices in miscarriage management following recent changes to state abortion laws and highlights the effect on healthcare access for pregnant individuals.

Significant Decline in Recommended Treatment Methods

The comprehensive analysis examined the medical care of nearly 123,600 commercially insured patients who experienced pregnancy loss between 2018 and 2024, spanning periods before and after the Supreme Court’s Dobbs decision. Researchers observed a marked decline in the use of the preferred two-drug regimen—mifepristone misoprostol—for miscarriage treatment in areas with stringent state abortion laws. Instead, medical teams increasingly resorted to misoprostol-only administration, despite clinical guidance favoring combination therapy to minimize complications such as hemorrhage and infection.

Rising Rates of Expectant Management and Misoprostol-Only Use

Findings reveal a 3% rise in expectant management, an approach in which no active treatment is provided and the body expels pregnancy tissue naturally, often resulting in extended or unpredictable recovery times. There was also a nearly 14% increase in the use of misoprostol-only medications for miscarriage, moving away from established best practices. These shifts suggest that patients in Arizona and similar states may receive less effective or potentially riskier care due to legislative changes.

Abortion Bans Drive Changes in Miscarriage Management

According to the study, states enforcing strict abortion bans, such as Arizona, Alabama, Louisiana, and Texas, have also criminalized the possession and distribution of the medications central to both medication abortion and miscarriage management. This regulatory environment has made it increasingly complex for healthcare providers to prescribe or dispense essential pregnancy medication, directly impacting the quality of care. As a result, clinicians now navigate heightened legal risks, with many more hesitant to offer treatments they previously considered standard.

Impact on Arizona Healthcare Access and Patient Outcomes

Within Arizona, shifts in miscarriage management strategies are already impacting healthcare access, particularly for patients relying on local hospitals and clinics. As medical professionals face mounting uncertainties, some patients must travel out of state, endure longer wait times, or forgo critical treatment altogether. Advocates warn that these conditions place additional strain on local healthcare systems and elevate the risk of adverse health outcomes, including infections and prolonged suffering due to delayed or inadequate care.

Drug Restrictions and Patient Safety Concerns

In addition to legislative efforts, increased drug restrictions in states with abortion bans hamper the use of FDA-approved regimens for miscarriage and pregnancy termination. Policymakers’ efforts to block access to mifepristone and related medications have prompted concerns from leading medical associations, which maintain that the combined mifepristone-misoprostol protocol remains the safest and most effective option for most patients.

Calls for Policy Review and Protection of Standard Care

The study’s authors and healthcare advocates are urging Arizona lawmakers to reevaluate current state abortion laws and their unintended consequences on patients experiencing pregnancy complications. They emphasize the importance of safeguarding access to evidence-based treatment, ensuring that local providers can deliver appropriate care without fear of legal repercussions. As the debate over reproductive healthcare intensifies in Arizona and nationwide, patient safety and the preservation of medical standards are expected to remain central issues in policy discussions.